PDF(Pubmed)
Abstract：
UNASSIGNED: Positron emission tomography with computed tomography (PET-CT) using fluorine 18-fluorodeoxyglucose (F-18 FDG) is increasingly used to stage patients with locally advanced breast cancer and for assessing treatment response after neoadjuvant chemotherapy (NACT).
UNASSIGNED: The aim of the study was to assess the correlation between PET-CT parameters and pathologic response of breast primary after NACT in breast cancer patients and to devise a grading system called NIMS grading system for response assessment using PET quantitative parameters.
UNASSIGNED: 55 patients who underwent F-18 FDG PET-CT before starting the therapy and again after completion of therapy were identified and included in the study. The clinical data and the histopathologic findings were recorded. All the patients received chemotherapy followed by surgery with axillary lymph node dissection. The PET-CT results were interpreted both qualitatively by visual analysis and quantitatively by estimating maximum Standardized uptake values(SUVmax) and other parameters - SUVmean, SUL, SUVBSA, Metabolic tumor volume (MTV) and Total lesion glycolysis (TLG).
UNASSIGNED: The sensitivity and specificity of F-18 FDG PET-CT to detect the residual disease after neoadjuvant chemotherapy was 75.6% & 92.8% respectively. Differences between complete response and residual disease were significant for ΔSUVmax(p=0.005), ΔSUVmean(p=0.006), ΔSUL (0.005) and ΔSUVBSA(0.004), while ΔMTV and ΔTLG were not significantly different between the two groups. The new NIMS grading system included scoring of ΔSUVmax, ΔSUVBSA, ΔTLG and ΔMTV on scale of 1 to 4 and correlated well with PERCIST criteria.
UNASSIGNED: F-18 FDG PET-CT had a good accuracy in the detection of residual disease after completion of NACT. Pre chemotherapy PET-CT is not adequate to predict the response of primary tumour to chemotherapy. However, changes in the values of various PET-CT parameters are a sensitive tool to assess the response to chemotherapy. The new grading system is easy to use and showed good correlation to PERCIST.
UNASSIGNED: The aim of the study was to assess the correlation between PET-CT parameters and pathologic response of breast primary after NACT in breast cancer patients and to devise a grading system called NIMS grading system for response assessment using PET quantitative parameters.
UNASSIGNED: 55 patients who underwent F-18 FDG PET-CT before starting the therapy and again after completion of therapy were identified and included in the study. The clinical data and the histopathologic findings were recorded. All the patients received chemotherapy followed by surgery with axillary lymph node dissection. The PET-CT results were interpreted both qualitatively by visual analysis and quantitatively by estimating maximum Standardized uptake values(SUVmax) and other parameters - SUVmean, SUL, SUVBSA, Metabolic tumor volume (MTV) and Total lesion glycolysis (TLG).
UNASSIGNED: The sensitivity and specificity of F-18 FDG PET-CT to detect the residual disease after neoadjuvant chemotherapy was 75.6% & 92.8% respectively. Differences between complete response and residual disease were significant for ΔSUVmax(p=0.005), ΔSUVmean(p=0.006), ΔSUL (0.005) and ΔSUVBSA(0.004), while ΔMTV and ΔTLG were not significantly different between the two groups. The new NIMS grading system included scoring of ΔSUVmax, ΔSUVBSA, ΔTLG and ΔMTV on scale of 1 to 4 and correlated well with PERCIST criteria.
UNASSIGNED: F-18 FDG PET-CT had a good accuracy in the detection of residual disease after completion of NACT. Pre chemotherapy PET-CT is not adequate to predict the response of primary tumour to chemotherapy. However, changes in the values of various PET-CT parameters are a sensitive tool to assess the response to chemotherapy. The new grading system is easy to use and showed good correlation to PERCIST.
摘要：
■使用氟18-氟脱氧葡萄糖（F-18FDG）的计算机断层扫描（PET-CT）的正电子发射断层扫描越来越多地用于对局部晚期乳腺癌患者进行分期，并评估新辅助化疗（NACT）后的治疗反应。
■本研究的目的是评估PET-CT参数与乳腺癌患者NACT后乳腺原发病理反应之间的相关性，并设计一种称为NIMS分级系统的分级系统，用于使用PET定量参数进行反应评估。
■55例患者在开始治疗前和完成治疗后再次接受F-18FDGPET-CT检查，并纳入研究。记录临床资料和组织病理学结果。所有患者均接受化疗，然后进行腋窝淋巴结清扫手术。PET-CT结果通过视觉分析定性解释，并通过估计最大标准化摄取值（SUVmax）和其他参数（SUVmean）定量解释。SUL,SUVBSA,代谢性肿瘤体积(MTV)和总病变糖酵解(TLG)。
■F-18FDGPET-CT检测新辅助化疗后残留病变的敏感性和特异性分别为75.6%和92.8%。完全缓解和残留疾病之间的差异对于ΔSUVmax（p=0.005），ΔSUVmean（p=0.006），ΔSUL(0.005)和ΔSUVBSA(0.004)，而ΔMTV和ΔTLG在两组之间没有显着差异。新的NIMS评分系统包括ΔSUVmax的评分，ΔSUVBSA,ΔTLG和ΔMTV在1至4的范围内，与PERCIST标准密切相关。
■F-18FDGPET-CT在完成NACT后检测残留病变方面具有良好的准确性。化疗前PET-CT不足以预测原发肿瘤对化疗的反应。然而,各种PET-CT参数值的变化是评估化疗反应的敏感工具.新的分级系统易于使用，并且与PERCIST具有良好的相关性。
■本研究的目的是评估PET-CT参数与乳腺癌患者NACT后乳腺原发病理反应之间的相关性，并设计一种称为NIMS分级系统的分级系统，用于使用PET定量参数进行反应评估。
■55例患者在开始治疗前和完成治疗后再次接受F-18FDGPET-CT检查，并纳入研究。记录临床资料和组织病理学结果。所有患者均接受化疗，然后进行腋窝淋巴结清扫手术。PET-CT结果通过视觉分析定性解释，并通过估计最大标准化摄取值（SUVmax）和其他参数（SUVmean）定量解释。SUL,SUVBSA,代谢性肿瘤体积(MTV)和总病变糖酵解(TLG)。
■F-18FDGPET-CT检测新辅助化疗后残留病变的敏感性和特异性分别为75.6%和92.8%。完全缓解和残留疾病之间的差异对于ΔSUVmax（p=0.005），ΔSUVmean（p=0.006），ΔSUL(0.005)和ΔSUVBSA(0.004)，而ΔMTV和ΔTLG在两组之间没有显着差异。新的NIMS评分系统包括ΔSUVmax的评分，ΔSUVBSA,ΔTLG和ΔMTV在1至4的范围内，与PERCIST标准密切相关。
■F-18FDGPET-CT在完成NACT后检测残留病变方面具有良好的准确性。化疗前PET-CT不足以预测原发肿瘤对化疗的反应。然而,各种PET-CT参数值的变化是评估化疗反应的敏感工具.新的分级系统易于使用，并且与PERCIST具有良好的相关性。
